


# **Supplement: OpenSAFELY: Do adults prescribed Non-steroidal anti-inflammatory drugs have an increased risk of death from COVID-19?**

## Contents


|   |    |
|---|----|
| eFigure 1. Illustration of the follow up .....  | 3  |
| eFigure 2. Directed Acyclic Graph for the association between NSAIDs and COVID-19 related deaths. ....  | 4  |
| eFigure 3. Time to COVID-19 related death by treatment group in Kaplan-Meier plot – General population.....   | 5  |
| eFigure 4. Cumulative mortality by exposure group, standardized to the covariate distribution of the exposure group - General population .....                              | 6  |
| eTable 1. Association between any oral NSAIDs and COVID-19 death .....  | 7  |
| eTable 2. Association between any oral NSAIDs and COVID-19 death, Age interaction ....  | 8  |
| eTable 3. Testing the PH assumption for COVID-19 Death in the main analysis .....   | 9  |
| eFigure 5. Schoenfeld residuals – General population .....  | 10 |
| eFigure 6. Time to COVID-19 related death by treatment group in Kaplan-Meier plot – osteoarthritis/ rheumatoid arthritis population.....                                    | 11 |
| eFigure 7. Cumulative mortality by exposure group, standardized to the covariate distribution of the exposure group - osteoarthritis/ rheumatoid arthritis population ..... | 12 |
| eTable 4. 1 by 1 comorbidity adjustments (after age/sex adjustments and stratified by regions) – osteoarthritis/ rheumatoid arthritis population.....                       | 13 |
| eFigure 8. Schoenfeld residuals – osteoarthritis/ rheumatoid arthritis population .....   | 16 |
| eTable 5. Descriptive Characteristics in people prescribed NSAIDs in the past 3 years, stratified by naproxen dose .....  | 17 |
| eTable 6. Descriptive Characteristics in people with osteoarthritis/ rheumatoid arthritis, stratified by naproxen dose .....  | 19 |
| eTable 7. Descriptive Characteristics in people prescribed NSAIDs in the past 3 years, stratified by COX-2 specific NSAIDs .....  | 21 |
| eTable 8. Descriptive Characteristics in people with osteoarthritis/ rheumatoid arthritis, stratified by COX-2 specific NSAIDs .....  | 23 |
| eTable 9. Descriptive Characteristics in people prescribed NSAIDs in the past 3 years, stratified by ibuprofen.....   | 25 |
| eTable 10. Descriptive Characteristics in people with osteoarthritis/ rheumatoid arthritis, stratified by ibuprofen.....  | 27 |
| eFigure 9. Time to COVID-19 related death by types of NSAIDs in Kaplan-Meier plot – General population.....   | 29 |

|  |    |
|--|----|
| eFigure 10. Time to COVID-19 related death by types of NSAIDs in Kaplan-Meier plot – osteoarthritis/ rheumatoid arthritis population.....                                    | 30 |
| eTable 11. Association between low dose naproxen, high dose naproxen and other NSAIDs and COVID-19 compared with non-use of NSAIDs .....                                     | 31 |
| eTable 12. Association between COX-2 specific NSAIDs, non-specific NSAIDs with COVID-19 death compared with non-use of NSAIDs .....  | 32 |
| eTable 13. Association between ibuprofen, other NSAIDs with COVID-19 death compared with non-use of NSAIDs.....  | 33 |
| eTable 14. Sensitivity analysis that excluding people ever prescribed aspirin.....   | 34 |
| eTable 15. <i>Post-hoc</i> analysis that using Directed Acyclic Graph approach to select covariates .....  | 35 |
| eTable 16. Sensitivity analysis that additionally adjusting for ethnicity in the fully adjusted models .....   | 36 |
| eTable 17. Sensitivity analysis that additionally adjusted for GP consultation and A&E attendance in the fully adjusted models .....   | 37 |
| eTable 18. Sensitivity analysis that separating HbA1c no measures category from uncontrolled diabetes category in the fully adjusted models .....                            | 38 |
| eTable 19. Sensitivity analysis that using 2 months to be the timeframe to identify exposure status .....  | 39 |
| eTable 20. Sensitivity analysis that removing indomethacin from exposure of interest .....   | 40 |
| eTable 21. Sensitivity analysis that not censoring people at NSAID prescription after study start date in the non-use of NSAID group as an intention-to-treat analysis ..... | 41 |
| eFigure 11. E-value for the upper 95% CI and point estimate in people with rheumatoid arthritis/ osteoarthritis .....  | 42 |


**eFigure 1. Illustration of the follow up**




**eFigure 2. Directed Acyclic Graph for the association between NSAIDs and COVID-19 related deaths.**



**eFigure 3. Time to COVID-19 related death by treatment group in Kaplan-Meier plot – General population**



**eFigure 4. Cumulative mortality by exposure group, standardized to the covariate distribution of the exposure group - General population**



eFigure 4 (a) presents cumulative mortality predicted from a Royston-Parmar model including all covariates from the fully adjusted Cox model, with the baseline hazard parametrized as a 3-degrees-of-freedom cubic spline; predictions standardized to the covariate distribution of the exposure group.  
eFigure 4 (b) presents difference between two curves in eFigure 4 (a).

**eTable 1. Association between any oral NSAIDs and COVID-19 death**

|  | Number of deaths | Total person-week | Rate per 1000 | Univariable |             | Age/Sex Adjusted |             | Fully Adjusted <sup>a</sup> |             |
|--|------------------|-------------------|---------------|-------------|-------------|------------------|-------------|-----------------------------|-------------|
|  |                  |                   |               | HR          | 95% CI      | HR               | 95% CI      | HR                          | 95% CI      |
| <b>Study population 1: General population (NSAIDs prescribed cohort)</b> |                  |                   |               |             |             |                  |             |                             |             |
| <b>Non-use of NSAID</b>  | 611              | 28,052,265        | 0.02          | 1.00 (ref)  |             | 1.00 (ref)       |             | 1.00 (ref)                  |             |
| <b>Current use of NSAIDs</b>   | 218              | 8,022,617         | 0.03          | 1.25        | 1.07 - 1.46 | 1.08             | 0.93 - 1.27 | 0.95                        | 0.80 - 1.13 |
| <b>Study population 2: Rheumatoid arthritis/ osteoarthritis cohort</b>   |                  |                   |               |             |             |                  |             |                             |             |
| <b>Non-use of NSAID</b>  | 2441             | 22,630,443        | 0.11          | 1.00 (ref)  |             | 1.00 (ref)       |             | 1.00 (ref)                  |             |
| <b>Current use of NSAIDs</b>   | 123              | 2,629,585         | 0.05          | 0.43        | 0.36 - 0.52 | 0.84             | 0.70 - 1.00 | 0.78                        | 0.65 - 0.94 |

<sup>a</sup>Adjusted for age, sex, obesity, smoking status, deprivation, chronic kidney disease, hypertension, heart failure, other heart diseases, diabetes severity, chronic obstructive pulmonary disease, other respiratory diseases, immunosuppression, cancer, rheumatoid arthritis (study population 1), osteoarthritis (study population 1), rheumatoid arthritis/osteoarthritis/both (study population 2), statins, proton pump inhibitors, oral prednisolone, hydroxychloroquine, other DMARDs, flu vaccine and pneumococcal vaccine.

**eTable 2. Association between any oral NSAIDs and COVID-19 death, Age interaction**

|  |                              | Number<br>of<br>deaths | Total<br>person-<br>week | Rate<br>per<br>1000 | Univariable |             |                     | Age/Sex Adjusted |             |                     | Fully Adjusted <sup>a</sup> |             |                     |  |  |  |
|--|------------------------------|------------------------|--------------------------|---------------------|-------------|-------------|---------------------|------------------|-------------|---------------------|-----------------------------|-------------|---------------------|--|--|--|
|  |                              |                        |                          |                     | HR          | 95% CI      | p(inter-<br>action) | HR               | 95% CI      | p(inter-<br>action) | HR                          | 95% CI      | p(inter-<br>action) |  |  |  |
| <b>Study population 1: General population (NSAIDs prescribed cohort)</b> |                              |                        |                          |                     |             |             |                     |                  |             |                     |                             |             |                     |  |  |  |
| <b>Age group</b>   |                              |                        |                          |                     |             |             |                     |                  |             |                     |                             |             |                     |  |  |  |
| <b>&lt;70</b>  |                              |                        |                          |                     |             |             | <0.01               |                  |             | 0.13                |                             |             | 0.35                |  |  |  |
|  | <b>Non-use of NSAID</b>      | 224                    | 24,800,142               | 0.01                | 1.00 (ref)  |             |                     | 1.00 (ref)       |             |                     | 1.00 (ref)                  |             |                     |  |  |  |
|  | <b>Current use of NSAIDs</b> | 96                     | 6,854,957                | 0.01                | 1.55        | 1.22 - 1.97 |                     | 1.26             | 0.99 - 1.60 |                     | 1.04                        | 0.81 - 1.34 |                     |  |  |  |
| <b>≥70</b>   |                              |                        |                          |                     |             |             |                     |                  |             |                     |                             |             |                     |  |  |  |
|  | <b>Non-use of NSAID</b>      | 387                    | 3,252,123                | 0.12                | 1.00 (ref)  |             |                     | 1.00 (ref)       |             |                     | 1.00 (ref)                  |             |                     |  |  |  |
|  | <b>Current use of NSAIDs</b> | 122                    | 1,167,660                | 0.10                | 0.88        | 0.72 - 1.08 |                     | 0.98             | 0.80 - 1.21 |                     | 0.89                        | 0.72 - 1.11 |                     |  |  |  |
| <b>Study population 2: Rheumatoid arthritis/ osteoarthritis cohort</b>   |                              |                        |                          |                     |             |             |                     |                  |             |                     |                             |             |                     |  |  |  |
| <b>Age group</b>   |                              |                        |                          |                     |             |             |                     |                  |             |                     |                             |             |                     |  |  |  |
| <b>&lt;70</b>  |                              |                        |                          |                     |             |             | <0.01               |                  |             | 0.05                |                             |             | 0.21                |  |  |  |
|  | <b>Non-use of NSAID</b>      | 255                    | 12,372,125               | 0.02                | 1.00 (ref)  |             |                     | 1.00 (ref)       |             |                     | 1.00 (ref)                  |             |                     |  |  |  |
|  | <b>Current use of NSAIDs</b> | 40                     | 1,838,378                | 0.02                | 1.06        | 0.76 - 1.47 |                     | 1.12             | 0.81 - 1.57 |                     | 0.94                        | 0.67 - 1.31 |                     |  |  |  |
| <b>≥70</b>   |                              |                        |                          |                     |             |             |                     |                  |             |                     |                             |             |                     |  |  |  |
|  | <b>Non-use of NSAID</b>      | 2,186                  | 10,258,318               | 0.21                | 1.00 (ref)  |             |                     | 1.00 (ref)       |             |                     | 1.00 (ref)                  |             |                     |  |  |  |
|  | <b>Current use of NSAIDs</b> | 83                     | 791,206                  | 0.10                | 0.49        | 0.40 - 0.61 |                     | 0.75             | 0.60 - 0.93 |                     | 0.72                        | 0.58 - 0.91 |                     |  |  |  |


<sup>a</sup>Adjusted for age, sex, obesity, smoking status, deprivation, chronic kidney disease, hypertension, heart failure, other heart diseases, diabetes severity, chronic obstructive pulmonary disease, other respiratory diseases, immunosuppression, cancer, rheumatoid arthritis (study population 1), osteoarthritis (study population 1), rheumatoid arthritis/osteoarthritis/both (study population 2), statins, proton pump inhibitors, oral prednisolone, hydroxychloroquine, other DMARDs, flu vaccine and pneumococcal vaccine.

**eTable 3. Testing the PH assumption for COVID-19 Death in the main analysis**


|  | Univariable | Age/Sex Adjusted | Fully Adjusted <sup>a</sup> |
|--|-------------|------------------|-----------------------------|
|  | p-value     | p-value          | p-value                     |
| <b>Study population 1: General population (NSAIDs prescribed cohort)</b> |             |                  |                             |
| Treatment Exposure   | 0.32        | 0.40             | 0.26                        |
| <b>Study population 2: Rheumatoid arthritis/ osteoarthritis cohort</b>   |             |                  |                             |
| Treatment Exposure   | 0.24        | 0.96             | 0.89                        |

<sup>a</sup>Adjusted for age, sex, obesity, smoking status, deprivation, chronic kidney disease, hypertension, heart failure, other heart diseases, diabetes severity, chronic obstructive pulmonary disease, other respiratory diseases, immunosuppression, cancer, rheumatoid arthritis (study population 1), osteoarthritis (study population 1), rheumatoid arthritis/osteoarthritis/both (study population 2), statins, proton pump inhibitors, oral prednisolone, hydroxychloroquine, other DMARDs, flu vaccine and pneumococcal vaccine.


**eFigure 5. Schoenfeld residuals – General population**



**eFigure 6. Time to COVID-19 related death by treatment group in Kaplan-Meier plot – osteoarthritis/ rheumatoid arthritis population**



**eFigure 7. Cumulative mortality by exposure group, standardized to the covariate distribution of the exposure group - osteoarthritis/ rheumatoid arthritis population**



eFigure 7 (a) presents cumulative mortality predicted from a Royston-Parmar model including all covariates from the fully adjusted Cox model, with the baseline hazard parametrized as a 2-degrees-of-freedom cubic spline; predictions standardized to the covariate distribution of the exposure group. eFigure 7 (b) presents different between two curves in eFigure 7 (a).


**eTable 4. 1 by 1 comorbidity adjustments (after age/sex adjustments and stratified by regions) – osteoarthritis/ rheumatoid arthritis population**

|   | HR         | 95% CI      |
|---|------------|-------------|
| <b>Evidence of obesity (4 categories)</b>                           |            |             |
| Non-use   | 1.00 (ref) |             |
| current NSAID use   | 0.85       | 0.71 - 1.02 |
|   |            |             |
| <b>Smoking status (missing set to non)</b>                          |            |             |
| Non-use   | 1.00 (ref) |             |
| current NSAID use   | 0.86       | 0.72 - 1.04 |
|   |            |             |
| <b>Index of Multiple Deprivation</b>                                |            |             |
| Non-use   | 1.00 (ref) |             |
| current NSAID use   | 0.87       | 0.72 - 1.04 |
|   |            |             |
| <b>Chronic kidney disease</b>                                       |            |             |
| Non-use   | 1.00 (ref) |             |
| current NSAID use   | 0.88       | 0.73 - 1.05 |
|   |            |             |
| <b>Diagnosed hypertension</b>                                       |            |             |
| Non-use   | 1.00 (ref) |             |
| current NSAID use   | 0.87       | 0.72 - 1.04 |
|   |            |             |
| <b>Heart Failure</b>  |            |             |
| Non-use   | 1.00 (ref) |             |
| current NSAID use   | 0.89       | 0.74 - 1.06 |
|   |            |             |
| <b>Other Heart Diseases</b>   |            |             |
| Non-use   | 1.00 (ref) |             |
| current NSAID use   | 0.87       | 0.73 - 1.05 |
|   |            |             |
| <b>Diabetes Severity: group no Hb1AC with uncontrolled diabetes</b> |            |             |
| Non-use   | 1.00 (ref) |             |
| current NSAID use   | 0.88       | 0.73 - 1.06 |
|   |            |             |
| <b>COPD</b>   |            |             |
| Non-use   | 1.00 (ref) |             |
| current NSAID use   | 0.87       | 0.73 - 1.05 |
|   |            |             |
| <b>Other Respiratory Diseases</b>                                   |            |             |

|   |            |             |
|---|------------|-------------|
| <b>Non-use</b>                                  | 1.00 (ref) |             |
| <b>current NSAID use</b>                        | 0.87       | 0.73 - 1.05 |
|   |            |             |
| <b>Immunosuppressed (combination algorithm)</b> |            |             |
| <b>Non-use</b>                                  | 1.00 (ref) |             |
| <b>current NSAID use</b>                        | 0.87       | 0.72 - 1.04 |
|   |            |             |
| <b>Cancer</b>                                   |            |             |
| <b>Non-use</b>                                  | 1.00 (ref) |             |
| <b>current NSAID use</b>                        | 0.87       | 0.72 - 1.04 |
|   |            |             |
| <b>Rheumatoid arthritis/osteoarthritis/both</b> |            |             |
| <b>Non-use</b>                                  | 1.00 (ref) |             |
| <b>current NSAID use</b>                        | 0.84       | 0.70 - 1.01 |
|   |            |             |
| <b>Recent Statin</b>                            |            |             |
| <b>Non-use</b>                                  | 1.00 (ref) |             |
| <b>current NSAID use</b>                        | 0.87       | 0.72 - 1.04 |
|   |            |             |
| <b>Recent PPIs</b>                              |            |             |
| <b>Non-use</b>                                  | 1.00 (ref) |             |
| <b>current NSAID use</b>                        | 0.71       | 0.59 - 0.86 |
|   |            |             |
| <b>Recent oral prednisolone</b>                 |            |             |
| <b>Non-use</b>                                  | 1.00 (ref) |             |
| <b>current NSAID use</b>                        | 0.86       | 0.72 - 1.04 |
|   |            |             |
| <b>Recent hydroxychloroquine</b>                |            |             |
| <b>Non-use</b>                                  | 1.00 (ref) |             |
| <b>current NSAID use</b>                        | 0.86       | 0.72 - 1.03 |
|   |            |             |
| <b>Recent Other DMARDs use</b>                  |            |             |
| <b>Non-use</b>                                  | 1.00 (ref) |             |
| <b>current NSAID use</b>                        | 0.85       | 0.71 - 1.02 |
|   |            |             |
| <b>Flu vaccine</b>                              |            |             |
| <b>Non-use</b>                                  | 1.00 (ref) |             |
| <b>current NSAID use</b>                        | 0.87       | 0.72 - 1.04 |
|   |            |             |
| <b>Pneumococcal Vaccine</b>                     |            |             |
| <b>Non-use</b>                                  | 1.00 (ref) |             |

|  |            |             |
|--|------------|-------------|
| <b>current NSAID use</b>                             | 0.87       | 0.72 - 1.04 |
|  |            |             |
| <b>GP consultation in last year (binary)</b>         |            |             |
| <b>Non-use</b>                                       | 1.00 (ref) |             |
| <b>current NSAID use</b>                             | 0.88       | 0.73 - 1.06 |
|  |            |             |
| <b>A&amp;E attendance rate in last year (binary)</b> |            |             |
| <b>Non-use</b>                                       | 1.00 (ref) |             |
| <b>current NSAID use</b>                             | 0.86       | 0.71 - 1.03 |

**eFigure 8. Schoenfeld residuals – osteoarthritis/ rheumatoid arthritis population**



**eTable 5. Descriptive Characteristics in people prescribed NSAIDs in the past 3 years, stratified by naproxen dose**

|  | Non-use of NSAIDs | Current use of naproxen low dose | Current use of naproxen high dose | Current use of other NSAIDs |
|--|-------------------|----------------------------------|-----------------------------------|-----------------------------|
| <b>Total</b>                               | 1,924,095         | 109,407                          | 291,943                           | 134,169                     |
| <b>Age as of 1<sup>st</sup> March 2020</b> |                   |                                  |                                   |                             |
| 18-<40                                     | 596,594 (31.0)    | 23,442 (21.4)                    | 69,581 (23.8)                     | 22,455 (16.7)               |
| 40-<50                                     | 396,273 (20.6)    | 19,203 (17.6)                    | 62,597 (21.4)                     | 20,999 (15.7)               |
| 50-<60                                     | 423,583 (22.0)    | 25,215 (23.0)                    | 78,077 (26.7)                     | 29,596 (22.1)               |
| 60-<70                                     | 283,615 (14.7)    | 22,529 (20.6)                    | 53,655 (18.4)                     | 29,985 (22.3)               |
| 70-<80                                     | 169,290 (8.8)     | 14,720 (13.5)                    | 23,907 (8.2)                      | 23,564 (17.6)               |
| 80+  | 54,740 (2.8)      | 4,298 (3.9)                      | 4,126 (1.4)                       | 7,570 (5.6)                 |
| <b>Sex</b>                                 |                   |                                  |                                   |                             |
| Female                                     | 1,091,674 (56.7)  | 68,751 (62.8)                    | 161,935 (55.5)                    | 86,158 (64.2)               |
| Male                                       | 832,421 (43.3)    | 40,656 (37.2)                    | 130,008 (44.5)                    | 48,011 (35.8)               |
| <b>Body mass index</b>                     |                   |                                  |                                   |                             |
| <18.5                                      | 26,253 (1.4)      | 1,367 (1.2)                      | 2,707 (0.9)                       | 1,865 (1.4)                 |
| 18.5-24.9                                  | 483,174 (25.1)    | 24,759 (22.6)                    | 60,247 (20.6)                     | 29,278 (21.8)               |
| 25-29.9                                    | 575,669 (29.9)    | 33,134 (30.3)                    | 86,445 (29.6)                     | 39,533 (29.5)               |
| 30-34.9                                    | 331,806 (17.2)    | 21,421 (19.6)                    | 57,799 (19.8)                     | 26,762 (19.9)               |
| 35-39.9                                    | 137,267 (7.1)     | 9,803 (9.0)                      | 27,277 (9.3)                      | 13,168 (9.8)                |
| 40+  | 70,666 (3.7)      | 5,725 (5.2)                      | 16,593 (5.7)                      | 7,833 (5.8)                 |
| Missing                                    | 299,260 (15.6)    | 13,198 (12.1)                    | 40,875 (14.0)                     | 15,730 (11.7)               |
| <b>Ethnicity</b>                           |                   |                                  |                                   |                             |
| White                                      | 1,229,872 (63.9)  | 71,738 (65.6)                    | 194,488 (66.6)                    | 89,226 (66.5)               |
| Mixed                                      | 20,415 (1.1)      | 1,000 (0.9)                      | 2,714 (0.9)                       | 955 (0.7)                   |
| Asian or Asian British                     | 151,756 (7.9)     | 8,740 (8.0)                      | 17,421 (6.0)                      | 6,877 (5.1)                 |
| Black                                      | 49,486 (2.6)      | 2,239 (2.0)                      | 6,327 (2.2)                       | 1,962 (1.5)                 |
| Other                                      | 30,211 (1.6)      | 1,523 (1.4)                      | 3,962 (1.4)                       | 1,441 (1.1)                 |
| Missing                                    | 442,355 (23.0)    | 24,167 (22.1)                    | 67,031 (23.0)                     | 33,708 (25.1)               |
| <b>Index of Multiple Deprivation</b>       |                   |                                  |                                   |                             |
| 1 (least deprived)                         | 387,308 (20.1)    | 21,563 (19.7)                    | 57,493 (19.7)                     | 28,083 (20.9)               |
| 2  | 385,477 (20.0)    | 21,510 (19.7)                    | 58,782 (20.1)                     | 28,203 (21.0)               |
| 3  | 381,088 (19.8)    | 22,019 (20.1)                    | 57,416 (19.7)                     | 27,785 (20.7)               |
| 4  | 384,665 (20.0)    | 22,247 (20.3)                    | 58,478 (20.0)                     | 25,991 (19.4)               |
| 5 (most deprived)                          | 385,557 (20.0)    | 22,068 (20.2)                    | 59,774 (20.5)                     | 24,107 (18.0)               |
| <b>Smoking status</b>                      |                   |                                  |                                   |                             |
| Never                                      | 839,206 (43.6)    | 46,595 (42.6)                    | 117,610 (40.3)                    | 55,514 (41.4)               |
| Former                                     | 665,175 (34.6)    | 41,754 (38.2)                    | 111,018 (38.0)                    | 54,603 (40.7)               |
| Current                                    | 388,410 (20.2)    | 19,863 (18.2)                    | 60,299 (20.7)                     | 22,801 (17.0)               |
| Missing                                    | 31,304 (1.6)      | 1,195 (1.1)                      | 3,016 (1.0)                       | 1,251 (0.9)                 |
| <b>Comorbidities</b>                       |                   |                                  |                                   |                             |
| Hypertension                               | 354,165 (18.4)    | 27,642 (25.3)                    | 60,641 (20.8)                     | 39,825 (29.7)               |
| Heart Failure                              | 9,477 (0.5)       | 530 (0.5)                        | 1,008 (0.3)                       | 893 (0.7)                   |
| Other Heart Disease                        | 28,010 (1.5)      | 1,878 (1.7)                      | 4,177 (1.4)                       | 2,676 (2.0)                 |
| Diabetes                                   | 177,116 (9.2)     | 13,083 (12.0)                    | 29,354 (10.1)                     | 17,300 (12.9)               |
| Controlled (HbA1c < 58mmols/mol)           | 122,377 (6.4)     | 9,410 (8.6)                      | 20,364 (7.0)                      | 12,189 (9.1)                |
| Uncontrolled (HbA1c ≥ 58mmols/mol)         | 50,205 (2.6)      | 3,417 (3.1)                      | 8,312 (2.8)                       | 4,745 (3.5)                 |

|                            |                |               |                |               |
|----------------------------|----------------|---------------|----------------|---------------|
| HbA1c not measured         | 4,534 (0.2)    | 256 (0.2)     | 678 (0.2)      | 366 (0.3)     |
| COPD                       | 42,690 (2.2)   | 3,295 (3.0)   | 7,050 (2.4)    | 5,115 (3.8)   |
| Other respiratory diseases | 17,328 (0.9)   | 1,266 (1.2)   | 2,609 (0.9)    | 2,322 (1.7)   |
| Cancer                     | 95,270 (5.0)   | 6,759 (6.2)   | 14,302 (4.9)   | 11,083 (8.3)  |
| Immunosuppression          | 9,263 (0.5)    | 558 (0.5)     | 1,393 (0.5)    | 939 (0.7)     |
| Chronic kidney disease     | 51,696 (2.7)   | 4,048 (3.7)   | 6,389 (2.2)    | 7,131 (5.3)   |
| Osteoarthritis             | 368,747 (19.2) | 34,024 (31.1) | 77,380 (26.5)  | 51,501 (38.4) |
| Rheumatoid arthritis       | 28,626 (1.5)   | 3,564 (3.3)   | 8,131 (2.8)    | 9,739 (7.3)   |
| <b>GP consultations</b>    |                |               |                |               |
| Median, IQR                | 5 (2-10)       | 8 (4-13)      | 7 (4-12)       | 8 (4-14)      |
| Min, Max                   | 0, 626         | 0, 393        | 0, 560         | 0, 576        |
| <b>A&amp;E attendance</b>  |                |               |                |               |
| Median, IQR                | 0 (0-0)        | 0 (0-0)       | 0 (0-0)        | 0 (0-0)       |
| Min, Max                   | 0, 127         | 0, 55         | 0, 153         | 0, 72         |
| <b>Vaccination</b>         |                |               |                |               |
| Flu                        | 434,986 (22.6) | 35,209 (32.2) | 71,967 (24.7)  | 54,721 (40.8) |
| Pneumococcal               | 116,372 (6.0)  | 9,618 (8.8)   | 20,494 (7.0)   | 14,696 (11.0) |
| <b>Medications</b>         |                |               |                |               |
| Statin                     | 223,756 (11.6) | 19,468 (17.8) | 40,157 (13.8)  | 27,651 (20.6) |
| Proton pump inhibitors     | 268,804 (14.0) | 72,119 (65.9) | 188,422 (64.5) | 81,584 (60.8) |
| Oral prednisolone          | 38,988 (2.0)   | 3,118 (2.8)   | 7,278 (2.5)    | 5,643 (4.2)   |
| Hydroxychloroquine         | 8,076 (0.4)    | 1,124 (1.0)   | 2,582 (0.9)    | 2,967 (2.2)   |
| Other DMARDs               | 20,742 (1.1)   | 2,720 (2.5)   | 6,124 (2.1)    | 7,943 (5.9)   |

Abbreviations: COPD, Chronic obstructive pulmonary disease; DMARDs, Disease-modifying antirheumatic drugs.

**eTable 6. Descriptive Characteristics in people with osteoarthritis/ rheumatoid arthritis, stratified by naproxen dose**

|  | Non-use of NSAIDs | Current use of naproxen low dose | Current use of naproxen high dose | Current use of other NSAIDs |
|--|-------------------|----------------------------------|-----------------------------------|-----------------------------|
| <b>Total</b>                               | 1,535,421         | 36,118                           | 82,438                            | 57,075                      |
| <b>Age as of 1<sup>st</sup> March 2020</b> |                   |                                  |                                   |                             |
| 18-<40                                     | 32,939 (2.1)      | 741 (2.1)                        | 2,379 (2.9)                       | 1,281 (2.2)                 |
| 40-<50                                     | 97,892 (6.4)      | 2,701 (7.5)                      | 8,931 (10.8)                      | 4,176 (7.3)                 |
| 50-<60                                     | 292,583 (19.1)    | 8,130 (22.5)                     | 25,488 (30.9)                     | 11,808 (20.7)               |
| 60-<70                                     | 417,085 (27.2)    | 11,928 (33.0)                    | 27,445 (33.3)                     | 17,661 (30.9)               |
| 70-<80                                     | 437,103 (28.5)    | 9,569 (26.5)                     | 15,346 (18.6)                     | 16,472 (28.9)               |
| 80+  | 257,819 (16.8)    | 3,049 (8.4)                      | 2,849 (3.5)                       | 5,677 (9.9)                 |
| <b>Sex</b>                                 |                   |                                  |                                   |                             |
| Female                                     | 952,830 (62.1)    | 23,946 (66.3)                    | 48,643 (59.0)                     | 38,062 (66.7)               |
| Male                                       | 582,591 (37.9)    | 12,172 (33.7)                    | 33,795 (41.0)                     | 19,013 (33.3)               |
| <b>Body mass index</b>                     |                   |                                  |                                   |                             |
| <18.5                                      | 18,953 (1.2)      | 261 (0.7)                        | 417 (0.5)                         | 541 (0.9)                   |
| 18.5-24.9                                  | 377,596 (24.6)    | 6,869 (19.0)                     | 13,422 (16.3)                     | 11,094 (19.4)               |
| 25-29.9                                    | 520,008 (33.9)    | 11,779 (32.6)                    | 25,785 (31.3)                     | 17,842 (31.3)               |
| 30-34.9                                    | 299,254 (19.5)    | 8,284 (22.9)                     | 19,636 (23.8)                     | 12,681 (22.2)               |
| 35-39.9                                    | 119,714 (7.8)     | 3,936 (10.9)                     | 9,855 (12.0)                      | 6,366 (11.2)                |
| 40+  | 58,615 (3.8)      | 2,288 (6.3)                      | 6,249 (7.6)                       | 3,812 (6.7)                 |
| Missing                                    | 141,281 (9.2)     | 2,701 (7.5)                      | 7,074 (8.6)                       | 4,739 (8.3)                 |
| <b>Ethnicity</b>                           |                   |                                  |                                   |                             |
| White                                      | 1,088,418 (70.9)  | 25,595 (70.9)                    | 58,644 (71.1)                     | 40,142 (70.3)               |
| Mixed                                      | 6,536 (0.4)       | 187 (0.5)                        | 427 (0.5)                         | 208 (0.4)                   |
| Asian or Asian British                     | 51,832 (3.4)      | 1,878 (5.2)                      | 3,111 (3.8)                       | 2,018 (3.5)                 |
| Black                                      | 17,623 (1.1)      | 429 (1.2)                        | 1,209 (1.5)                       | 456 (0.8)                   |
| Other                                      | 10,867 (0.7)      | 278 (0.8)                        | 600 (0.7)                         | 358 (0.6)                   |
| Missing                                    | 360,145 (23.5)    | 7,751 (21.5)                     | 18,447 (22.4)                     | 13,893 (24.3)               |
| <b>Index of Multiple Deprivation</b>       |                   |                                  |                                   |                             |
| 1 (least deprived)                         | 312,861 (20.4)    | 6,294 (17.4)                     | 13,944 (16.9)                     | 10,449 (18.3)               |
| 2  | 308,559 (20.1)    | 6,719 (18.6)                     | 15,204 (18.4)                     | 10,928 (19.1)               |
| 3  | 307,577 (20.0)    | 7,031 (19.5)                     | 15,828 (19.2)                     | 11,638 (20.4)               |
| 4  | 309,012 (20.1)    | 7,770 (21.5)                     | 17,572 (21.3)                     | 12,085 (21.2)               |
| 5 (most deprived)                          | 297,412 (19.4)    | 8,304 (23.0)                     | 19,890 (24.1)                     | 11,975 (21.0)               |
| <b>Smoking status</b>                      |                   |                                  |                                   |                             |
| Never                                      | 672,558 (43.8)    | 14,950 (41.4)                    | 32,452 (39.4)                     | 22,847 (40.0)               |
| Former                                     | 694,377 (45.2)    | 16,703 (46.2)                    | 37,541 (45.5)                     | 26,906 (47.1)               |
| Current                                    | 164,760 (10.7)    | 4,413 (12.2)                     | 12,282 (14.9)                     | 7,236 (12.7)                |
| Missing                                    | 3,726 (0.2)       | 52 (0.1)                         | 163 (0.2)                         | 86 (0.2)                    |
| <b>Comorbidities</b>                       |                   |                                  |                                   |                             |
| Hypertension                               | 626,863 (40.8)    | 14,395 (39.9)                    | 28,270 (34.3)                     | 23,572 (41.3)               |
| Heart Failure                              | 36,915 (2.4)      | 311 (0.9)                        | 510 (0.6)                         | 591 (1.0)                   |
| Other Heart Disease                        | 58,170 (3.8)      | 889 (2.5)                        | 1,819 (2.2)                       | 1,505 (2.6)                 |
| Diabetes                                   |                   |                                  |                                   |                             |
| Controlled<br>(HbA1c <<br>58mmols/mol)     | 177,181 (11.5)    | 4,379 (12.1)                     | 8,571 (10.4)                      | 6,519 (11.4)                |
| Uncontrolled<br>(HbA1c ≥<br>58mmols/mol)   | 58,553 (3.8)      | 1,285 (3.6)                      | 2,890 (3.5)                       | 2,124 (3.7)                 |

|                            |                  |               |               |               |
|----------------------------|------------------|---------------|---------------|---------------|
| HbA1c not measured         | 3,675 (0.2)      | 91 (0.3)      | 175 (0.2)     | 151 (0.3)     |
| COPD                       | 86,193 (5.6)     | 1,839 (5.1)   | 3,459 (4.2)   | 3,101 (5.4)   |
| Other respiratory diseases | 38,360 (2.5)     | 721 (2.0)     | 1,281 (1.6)   | 1,428 (2.5)   |
| Cancer                     | 174,839 (11.4)   | 3,400 (9.4)   | 6,447 (7.8)   | 6,137 (10.8)  |
| Immunosuppression          | 8,496 (0.6)      | 184 (0.5)     | 415 (0.5)     | 395 (0.7)     |
| Chronic kidney disease     | 165,270 (10.8)   | 2,547 (7.1)   | 3,718 (4.5)   | 4,907 (8.6)   |
| Osteoarthritis             | 1,476,214 (96.1) | 34,024 (94.2) | 77,380 (93.9) | 51,501 (90.2) |
| Rheumatoid arthritis       | 94,851 (6.2)     | 3,564 (9.9)   | 8,131 (9.9)   | 9,739 (17.1)  |
| <b>GP consultations</b>    |                  |               |               |               |
| Median, IQR                | 6 (3-11)         | 9 (5-14)      | 8 (5-14)      | 9 (5-14)      |
| Min, Max                   | 0, 585           | 0, 360        | 0, 318        | 0, 260        |
| <b>A&amp;E attendance</b>  |                  |               |               |               |
| Median, IQR                | 0 (0-0)          | 0 (0-0)       | 0 (0-0)       | 0 (0-0)       |
| Min, Max                   | 0, 77            | 0, 28         | 0, 39         | 0, 59         |
| <b>Vaccination</b>         |                  |               |               |               |
| Flu                        | 807,032 (52.6)   | 18,893 (52.3) | 35,363 (42.9) | 32,303 (56.6) |
| Pneumococcal               | 193,115 (12.6)   | 5,282 (14.6)  | 10,671 (12.9) | 8,748 (15.3)  |
| <b>Medications</b>         |                  |               |               |               |
| Statin                     | 416,818 (27.1)   | 10,529 (29.2) | 20,047 (24.3) | 16,585 (29.1) |
| Proton pump inhibitors     | 372,180 (24.2)   | 29,382 (81.4) | 66,111 (80.2) | 41,930 (73.5) |
| Oral prednisolone          | 61,305 (4.0)     | 1,517 (4.2)   | 3,307 (4.0)   | 3,413 (6.0)   |
| Hydroxychloroquine         | 16,815 (1.1)     | 848 (2.3)     | 1,957 (2.4)   | 2,299 (4.0)   |
| Other DMARDs               | 48,752 (3.2)     | 2,081 (5.8)   | 4,587 (5.6)   | 6,031 (10.6)  |

Abbreviations: COPD, Chronic obstructive pulmonary disease; DMARDs, Disease-modifying antirheumatic drugs

**eTable 7. Descriptive Characteristics in people prescribed NSAIDs in the past 3 years, stratified by COX-2 specific NSAIDs**

|  | Non-use of NSAIDs | Current use of COX-2 specific | Current use of non-specific NSAIDs |
|--|-------------------|-------------------------------|------------------------------------|
| <b>Total</b>                               | 1,924,095         | 24,751                        | 510,768                            |
| <b>Age as of 1<sup>st</sup> March 2020</b> |                   |                               |                                    |
| 18-<40                                     | 596,594 (31.0)    | 3,199 (12.9)                  | 112,279 (22.0)                     |
| 40-<50                                     | 396,273 (20.6)    | 4,240 (17.1)                  | 98,559 (19.3)                      |
| 50-<60                                     | 423,583 (22.0)    | 6,590 (26.6)                  | 126,298 (24.7)                     |
| 60-<70                                     | 283,615 (14.7)    | 5,740 (23.2)                  | 100,429 (19.7)                     |
| 70-<80                                     | 169,290 (8.8)     | 3,842 (15.5)                  | 58,349 (11.4)                      |
| 80+  | 54,740 (2.8)      | 1,140 (4.6)                   | 14,854 (2.9)                       |
| <b>Sex</b>                                 |                   |                               |                                    |
| Female                                     | 1,091,674 (56.7)  | 15,447 (62.4)                 | 301,397 (59.0)                     |
| Male                                       | 832,421 (43.3)    | 9,304 (37.6)                  | 209,371 (41.0)                     |
| <b>Body mass index</b>                     |                   |                               |                                    |
| <18.5                                      | 26,253 (1.4)      | 274 (1.1)                     | 5,665 (1.1)                        |
| 18.5-24.9                                  | 483,174 (25.1)    | 5,325 (21.5)                  | 108,959 (21.3)                     |
| 25-29.9                                    | 575,669 (29.9)    | 7,580 (30.6)                  | 151,532 (29.7)                     |
| 30-34.9                                    | 331,806 (17.2)    | 5,028 (20.3)                  | 100,954 (19.8)                     |
| 35-39.9                                    | 137,267 (7.1)     | 2,538 (10.3)                  | 47,710 (9.3)                       |
| 40+  | 70,666 (3.7)      | 1,411 (5.7)                   | 28,740 (5.6)                       |
| Missing                                    | 299,260 (15.6)    | 2,595 (10.5)                  | 67,208 (13.2)                      |
| <b>Ethnicity</b>                           |                   |                               |                                    |
| White                                      | 1,229,872 (63.9)  | 17,141 (69.3)                 | 338,311 (66.2)                     |
| Mixed                                      | 20,415 (1.1)      | 128 (0.5)                     | 4,541 (0.9)                        |
| Asian or Asian British                     | 151,756 (7.9)     | 981 (4.0)                     | 32,057 (6.3)                       |
| Black                                      | 49,486 (2.6)      | 208 (0.8)                     | 10,320 (2.0)                       |
| Other                                      | 30,211 (1.6)      | 231 (0.9)                     | 6,695 (1.3)                        |
| Missing                                    | 442,355 (23.0)    | 6,062 (24.5)                  | 118,844 (23.3)                     |
| <b>Index of Multiple Deprivation</b>       |                   |                               |                                    |
| 1 (least deprived)                         | 387,308 (20.1)    | 5,517 (22.3)                  | 101,622 (19.9)                     |
| 2  | 385,477 (20.0)    | 5,621 (22.7)                  | 102,874 (20.1)                     |
| 3  | 381,088 (19.8)    | 5,202 (21.0)                  | 102,018 (20.0)                     |
| 4  | 384,665 (20.0)    | 4,543 (18.4)                  | 102,173 (20.0)                     |
| 5 (most deprived)                          | 385,557 (20.0)    | 3,868 (15.6)                  | 102,081 (20.0)                     |
| <b>Smoking status</b>                      |                   |                               |                                    |
| Never                                      | 839,206 (43.6)    | 9,751 (39.4)                  | 209,968 (41.1)                     |
| Former                                     | 665,175 (34.6)    | 10,690 (43.2)                 | 196,685 (38.5)                     |
| Current                                    | 388,410 (20.2)    | 4,212 (17.0)                  | 98,751 (19.3)                      |
| Missing                                    | 31,304 (1.6)      | 98 (0.4)                      | 5,364 (1.1)                        |
| <b>Comorbidities</b>                       |                   |                               |                                    |
| Hypertension                               | 354,165 (18.4)    | 7,512 (30.4)                  | 120,596 (23.6)                     |
| Heart Failure                              | 9,477 (0.5)       | 177 (0.7)                     | 2,254 (0.4)                        |
| Other Heart Disease                        | 28,010 (1.5)      | 506 (2.0)                     | 8,225 (1.6)                        |
| Diabetes                                   |                   |                               |                                    |
| Controlled (HbA1c < 58mmols/mol)           | 122,377 (6.4)     | 2,162 (8.7)                   | 39,801 (7.8)                       |

|  |                |               |                |
|--|----------------|---------------|----------------|
| Uncontrolled<br>(HbA1c ≥<br>58mmols/mol) | 50,205 (2.6)   | 772 (3.1)     | 15,702 (3.1)   |
| HbA1c not measured                       | 4,534 (0.2)    | 74 (0.3)      | 1,226 (0.2)    |
| COPD                                     | 42,690 (2.2)   | 985 (4.0)     | 14,475 (2.8)   |
| Other respiratory diseases               | 17,328 (0.9)   | 465 (1.9)     | 5,732 (1.1)    |
| Cancer                                   | 95,270 (5.0)   | 1,841 (7.4)   | 30,303 (5.9)   |
| Immunosuppression                        | 9,263 (0.5)    | 180 (0.7)     | 2,710 (0.5)    |
| Chronic kidney disease                   | 51,696 (2.7)   | 1,465 (5.9)   | 16,103 (3.2)   |
| Osteoarthritis                           | 368,747 (19.2) | 10,735 (43.4) | 152,170 (29.8) |
| Rheumatoid arthritis                     | 28,626 (1.5)   | 3,185 (12.9)  | 18,249 (3.6)   |
| <b>GP consultations</b>                  |                |               |                |
| Median, IQR                              | 5 (2-10)       | 9 (5-15)      | 7 (4-13)       |
| Min, Max                                 | 0, 626         | 0, 565        | 0, 576         |
| <b>A&amp;E attendance</b>                |                |               |                |
| Median, IQR                              | 0 (0-0)        | 0 (0-0)       | 0 (0-0)        |
| Min, Max                                 | 0, 127         | 0, 60         | 0, 153         |
| <b>Vaccination</b>                       |                |               |                |
| Flu                                      | 434,986 (22.6) | 10,489 (42.4) | 151,408 (29.6) |
| Pneumococcal                             | 116,372 (6.0)  | 3,302 (13.3)  | 41,506 (8.1)   |
| <b>Medications</b>                       |                |               |                |
| Statin                                   | 223,756 (11.6) | 4,940 (20.0)  | 82,336 (16.1)  |
| Proton pump inhibitors                   | 268,804 (14.0) | 16,375 (66.2) | 325,750 (63.8) |
| Oral prednisolone                        | 38,988 (2.0)   | 1,488 (6.0)   | 14,551 (2.8)   |
| Hydroxychloroquine                       | 8,076 (0.4)    | 1,035 (4.2)   | 5,638 (1.1)    |
| Other DMARDs                             | 20,742 (1.1)   | 2,844 (11.5)  | 13,943 (2.7)   |

Abbreviations: COPD, Chronic obstructive pulmonary disease; DMARDs, Disease-modifying antirheumatic drugs.

**eTable 8. Descriptive Characteristics in people with osteoarthritis/ rheumatoid arthritis, stratified by COX-2 specific NSAIDs**

|  | Non-use of NSAIDs | Current use of COX-2 specific | Current use of non-specific NSAIDs |
|--|-------------------|-------------------------------|------------------------------------|
| <b>Total</b>                               | 1,535,421         | 12,538                        | 163,093                            |
| <b>Age as of 1<sup>st</sup> March 2020</b> |                   |                               |                                    |
| 18-<40                                     | 32,939 (2.1)      | 458 (3.7)                     | 3,943 (2.4)                        |
| 40-<50                                     | 97,892 (6.4)      | 1,310 (10.4)                  | 14,498 (8.9)                       |
| 50-<60                                     | 292,583 (19.1)    | 3,144 (25.1)                  | 42,282 (25.9)                      |
| 60-<70                                     | 417,085 (27.2)    | 3,810 (30.4)                  | 53,224 (32.6)                      |
| 70-<80                                     | 437,103 (28.5)    | 2,897 (23.1)                  | 38,490 (23.6)                      |
| 80+  | 257,819 (16.8)    | 919 (7.3)                     | 10,656 (6.5)                       |
| <b>Sex</b>                                 |                   |                               |                                    |
| Female                                     | 952,830 (62.1)    | 8,714 (69.5)                  | 101,937 (62.5)                     |
| Male                                       | 582,591 (37.9)    | 3,824 (30.5)                  | 61,156 (37.5)                      |
| <b>Body mass index</b>                     |                   |                               |                                    |
| <18.5                                      | 18,953 (1.2)      | 117 (0.9)                     | 1,102 (0.7)                        |
| 18.5-24.9                                  | 377,596 (24.6)    | 2,519 (20.1)                  | 28,866 (17.7)                      |
| 25-29.9                                    | 520,008 (33.9)    | 3,935 (31.4)                  | 51,471 (31.6)                      |
| 30-34.9                                    | 299,254 (19.5)    | 2,737 (21.8)                  | 37,864 (23.2)                      |
| 35-39.9                                    | 119,714 (7.8)     | 1,437 (11.5)                  | 18,720 (11.5)                      |
| 40+  | 58,615 (3.8)      | 839 (6.7)                     | 11,510 (7.1)                       |
| Missing                                    | 141,281 (9.2)     | 954 (7.6)                     | 13,560 (8.3)                       |
| <b>Ethnicity</b>                           |                   |                               |                                    |
| White                                      | 1,088,418 (70.9)  | 8,867 (70.7)                  | 115,514 (70.8)                     |
| Mixed                                      | 6,536 (0.4)       | 36 (0.3)                      | 786 (0.5)                          |
| Asian or Asian British                     | 51,832 (3.4)      | 433 (3.5)                     | 6,574 (4.0)                        |
| Black                                      | 17,623 (1.1)      | 100 (0.8)                     | 1,994 (1.2)                        |
| Other                                      | 10,867 (0.7)      | 95 (0.8)                      | 1,141 (0.7)                        |
| Missing                                    | 360,145 (23.5)    | 3,007 (24.0)                  | 37,084 (22.7)                      |
| <b>Index of Multiple Deprivation</b>       |                   |                               |                                    |
| 1 (least deprived)                         | 312,861 (20.4)    | 2,300 (18.3)                  | 28,387 (17.4)                      |
| 2  | 308,559 (20.1)    | 2,401 (19.1)                  | 30,450 (18.7)                      |
| 3  | 307,577 (20.0)    | 2,586 (20.6)                  | 31,911 (19.6)                      |
| 4  | 309,012 (20.1)    | 2,627 (21.0)                  | 34,800 (21.3)                      |
| 5 (most deprived)                          | 297,412 (19.4)    | 2,624 (20.9)                  | 37,545 (23.0)                      |
| <b>Smoking status</b>                      |                   |                               |                                    |
| Never                                      | 672,558 (43.8)    | 4,932 (39.3)                  | 65,317 (40.0)                      |
| Former                                     | 694,377 (45.2)    | 5,888 (47.0)                  | 75,262 (46.1)                      |
| Current                                    | 164,760 (10.7)    | 1,699 (13.6)                  | 22,232 (13.6)                      |
| Missing                                    | 3,726 (0.2)       | 19 (0.2)                      | 282 (0.2)                          |
| <b>Comorbidities</b>                       |                   |                               |                                    |
| Hypertension                               | 626,863 (40.8)    | 4,800 (38.3)                  | 61,437 (37.7)                      |
| Heart Failure                              | 36,915 (2.4)      | 127 (1.0)                     | 1,285 (0.8)                        |
| Other Heart Disease                        | 58,170 (3.8)      | 332 (2.6)                     | 3,881 (2.4)                        |
| Diabetes                                   |                   |                               |                                    |
| Controlled (HbA1c < 58mmols/mol)           | 177,181 (11.5)    | 1,327 (10.6)                  | 18,142 (11.1)                      |

|  |                  |               |                |
|--|------------------|---------------|----------------|
| Uncontrolled<br>(HbA1c ≥<br>58mmols/mol) | 58,553 (3.8)     | 411 (3.3)     | 5,888 (3.6)    |
| HbA1c not measured                       | 3,675 (0.2)      | 39 (0.3)      | 378 (0.2)      |
| COPD                                     | 86,193 (5.6)     | 668 (5.3)     | 7,731 (4.7)    |
| Other respiratory diseases               | 38,360 (2.5)     | 342 (2.7)     | 3,088 (1.9)    |
| Cancer                                   | 174,839 (11.4)   | 1,154 (9.2)   | 14,830 (9.1)   |
| Immunosuppression                        | 8,496 (0.6)      | 100 (0.8)     | 894 (0.5)      |
| Chronic kidney disease                   | 165,270 (10.8)   | 1,089 (8.7)   | 10,083 (6.2)   |
| Osteoarthritis                           | 1,476,214 (96.1) | 10,735 (85.6) | 152,170 (93.3) |
| Rheumatoid arthritis                     | 94,851 (6.2)     | 3,185 (25.4)  | 18,249 (11.2)  |
| <b>GP consultations</b>                  |                  |               |                |
| Median, IQR                              | 6 (3-11)         | 10 (6-16)     | 8 (5-14)       |
| Min, Max                                 | 0, 585           | 0, 225        | 0, 360         |
| <b>A&amp;E attendance</b>                |                  |               |                |
| Median, IQR                              | 0 (0-0)          | 0 (0-0)       | 0 (0-0)        |
| Min, Max                                 | 0, 77            | 0, 26         | 0, 59          |
| <b>Vaccination</b>                       |                  |               |                |
| Flu                                      | 807,032 (52.6)   | 6,886 (54.9)  | 79,673 (48.9)  |
| Pneumococcal                             | 193,115 (12.6)   | 2,065 (16.5)  | 22,636 (13.9)  |
| <b>Medications</b>                       |                  |               |                |
| Statin                                   | 416,818 (27.1)   | 3,250 (25.9)  | 43,911 (26.9)  |
| Proton pump inhibitors                   | 372,180 (24.2)   | 9,026 (72.0)  | 128,397 (78.7) |
| Oral prednisolone                        | 61,305 (4.0)     | 965 (7.7)     | 7,272 (4.5)    |
| Hydroxychloroquine                       | 16,815 (1.1)     | 783 (6.2)     | 4,321 (2.6)    |
| Other DMARDs                             | 48,752 (3.2)     | 2,007 (16.0)  | 10,692 (6.6)   |

Abbreviations: COPD, Chronic obstructive pulmonary disease; DMARDs, Disease-modifying antirheumatic drugs.

**eTable 9. Descriptive Characteristics in people prescribed NSAIDs in the past 3 years, stratified by ibuprofen**

|  | Non-use of NSAIDs | Current use of Ibuprofen | Current use of other NSAIDs |
|--|-------------------|--------------------------|-----------------------------|
| <b>Total</b>                               | 1,924,095         | 50,603                   | 484,916                     |
| <b>Age as of 1<sup>st</sup> March 2020</b> |                   |                          |                             |
| 18-<40                                     | 596,594 (31.0)    | 6,621 (13.1)             | 108,857 (22.4)              |
| 40-<50                                     | 396,273 (20.6)    | 6,376 (12.6)             | 96,423 (19.9)               |
| 50-<60                                     | 423,583 (22.0)    | 10,321 (20.4)            | 122,567 (25.3)              |
| 60-<70                                     | 283,615 (14.7)    | 12,333 (24.4)            | 93,836 (19.4)               |
| 70-<80                                     | 169,290 (8.8)     | 11,010 (21.8)            | 51,181 (10.6)               |
| 80+  | 54,740 (2.8)      | 3,942 (7.8)              | 12,052 (2.5)                |
| <b>Sex</b>                                 |                   |                          |                             |
| Female                                     | 1,091,674 (56.7)  | 31,423 (62.1)            | 285,421 (58.9)              |
| Male                                       | 832,421 (43.3)    | 19,180 (37.9)            | 199,495 (41.1)              |
| <b>Body mass index</b>                     |                   |                          |                             |
| <18.5                                      | 26,253 (1.4)      | 763 (1.5)                | 5,176 (1.1)                 |
| 18.5-24.9                                  | 483,174 (25.1)    | 10,812 (21.4)            | 103,472 (21.3)              |
| 25-29.9                                    | 575,669 (29.9)    | 15,124 (29.9)            | 143,988 (29.7)              |
| 30-34.9                                    | 331,806 (17.2)    | 10,268 (20.3)            | 95,714 (19.7)               |
| 35-39.9                                    | 137,267 (7.1)     | 4,983 (9.8)              | 45,265 (9.3)                |
| 40+  | 70,666 (3.7)      | 2,975 (5.9)              | 27,176 (5.6)                |
| Missing                                    | 299,260 (15.6)    | 5,678 (11.2)             | 64,125 (13.2)               |
| <b>Ethnicity</b>                           |                   |                          |                             |
| White                                      | 1,229,872 (63.9)  | 33,514 (66.2)            | 321,938 (66.4)              |
| Mixed                                      | 20,415 (1.1)      | 355 (0.7)                | 4,314 (0.9)                 |
| Asian or Asian British                     | 151,756 (7.9)     | 2,964 (5.9)              | 30,074 (6.2)                |
| Black                                      | 49,486 (2.6)      | 842 (1.7)                | 9,686 (2.0)                 |
| Other                                      | 30,211 (1.6)      | 630 (1.2)                | 6,296 (1.3)                 |
| Missing                                    | 442,355 (23.0)    | 12,298 (24.3)            | 112,608 (23.2)              |
| <b>Index of Multiple Deprivation</b>       |                   |                          |                             |
| 1 (least deprived)                         | 387,308 (20.1)    | 9,514 (18.8)             | 97,625 (20.1)               |
| 2  | 385,477 (20.0)    | 9,843 (19.5)             | 98,652 (20.3)               |
| 3  | 381,088 (19.8)    | 10,560 (20.9)            | 96,660 (19.9)               |
| 4  | 384,665 (20.0)    | 10,029 (19.8)            | 96,687 (19.9)               |
| 5 (most deprived)                          | 385,557 (20.0)    | 10,657 (21.1)            | 95,292 (19.7)               |
| <b>Smoking status</b>                      |                   |                          |                             |
| Never                                      | 839,206 (43.6)    | 20,422 (40.4)            | 199,297 (41.1)              |
| Former                                     | 665,175 (34.6)    | 20,668 (40.8)            | 186,707 (38.5)              |
| Current                                    | 388,410 (20.2)    | 9,064 (17.9)             | 93,899 (19.4)               |
| Missing                                    | 31,304 (1.6)      | 449 (0.9)                | 5,013 (1.0)                 |
| <b>Comorbidities</b>                       |                   |                          |                             |
| Hypertension                               | 354,165 (18.4)    | 16,190 (32.0)            | 111,918 (23.1)              |
| Heart Failure                              | 9,477 (0.5)       | 385 (0.8)                | 2,046 (0.4)                 |
| Other Heart Disease                        | 28,010 (1.5)      | 1,093 (2.2)              | 7,638 (1.6)                 |
| Diabetes                                   |                   |                          |                             |
| Controlled<br>(HbA1c <<br>58mmols/mol)     | 122,377 (6.4)     | 5,354 (10.6)             | 36,609 (7.5)                |
| Uncontrolled                               | 50,205 (2.6)      | 2,238 (4.4)              | 14,236 (2.9)                |

|                            |                |               |                |
|----------------------------|----------------|---------------|----------------|
| (HbA1c ≥ 58mmols/mol)      |                |               |                |
| HbA1c not measured         | 4,534 (0.2)    | 138 (0.3)     | 1,162 (0.2)    |
| COPD                       | 42,690 (2.2)   | 2,317 (4.6)   | 13,143 (2.7)   |
| Other respiratory diseases | 17,328 (0.9)   | 1,032 (2.0)   | 5,165 (1.1)    |
| Cancer                     | 95,270 (5.0)   | 5,437 (10.7)  | 26,707 (5.5)   |
| Immunosuppression          | 9,263 (0.5)    | 415 (0.8)     | 2,475 (0.5)    |
| Chronic kidney disease     | 51,696 (2.7)   | 2,734 (5.4)   | 14,834 (3.1)   |
| Osteoarthritis             | 368,747 (19.2) | 20,641 (40.8) | 142,264 (29.3) |
| Rheumatoid arthritis       | 28,626 (1.5)   | 2,179 (4.3)   | 19,255 (4.0)   |
| <b>GP consultations</b>    |                |               |                |
| Median, IQR                | 5 (2-10)       | 8 (4-14)      | 7 (4-13)       |
| Min, Max                   | 0, 626         | 0, 576        | 0, 565         |
| <b>A&amp;E attendance</b>  |                |               |                |
| Median, IQR                | 0 (0-0)        | 0 (0-0)       | 0 (0-0)        |
| Min, Max                   | 0, 127         | 0, 72         | 0, 153         |
| <b>Vaccination</b>         |                |               |                |
| Flu                        | 434,986 (22.6) | 23,734 (46.9) | 138,163 (28.5) |
| Pneumococcal               | 116,372 (6.0)  | 5,906 (11.7)  | 38,902 (8.0)   |
| <b>Medications</b>         |                |               |                |
| Statin                     | 223,756 (11.6) | 12,185 (24.1) | 75,091 (15.5)  |
| Proton pump inhibitors     | 268,804 (14.0) | 32,922 (65.1) | 309,203 (63.8) |
| Oral prednisolone          | 38,988 (2.0)   | 1,930 (3.8)   | 14,109 (2.9)   |
| Hydroxychloroquine         | 8,076 (0.4)    | 615 (1.2)     | 6,058 (1.2)    |
| Other DMARDs               | 20,742 (1.1)   | 1,561 (3.1)   | 15,226 (3.1)   |

Abbreviations: COPD, Chronic obstructive pulmonary disease; DMARDs, Disease-modifying antirheumatic drugs.


**eTable 10. Descriptive Characteristics in people with osteoarthritis/ rheumatoid arthritis, stratified by ibuprofen**

|  | Non-use of NSAIDs | Current use of Ibuprofen | Current use of other NSAIDs |
|--|-------------------|--------------------------|-----------------------------|
| <b>Total</b>                               | 1,535,421         | 21,893                   | 153,738                     |
| <b>Age as of 1<sup>st</sup> March 2020</b> |                   |                          |                             |
| 18-<40                                     | 32,939 (2.1)      | 317 (1.4)                | 4,084 (2.7)                 |
| 40-<50                                     | 97,892 (6.4)      | 1,095 (5.0)              | 14,713 (9.6)                |
| 50-<60                                     | 292,583 (19.1)    | 3,686 (16.8)             | 41,740 (27.2)               |
| 60-<70                                     | 417,085 (27.2)    | 6,742 (30.8)             | 50,292 (32.7)               |
| 70-<80                                     | 437,103 (28.5)    | 7,246 (33.1)             | 34,141 (22.2)               |
| 80+  | 257,819 (16.8)    | 2,807 (12.8)             | 8,768 (5.7)                 |
| <b>Sex</b>                                 |                   |                          |                             |
| Female                                     | 952,830 (62.1)    | 14,429 (65.9)            | 96,222 (62.6)               |
| Male                                       | 582,591 (37.9)    | 7,464 (34.1)             | 57,516 (37.4)               |
| <b>Body mass index</b>                     |                   |                          |                             |
| <18.5                                      | 18,953 (1.2)      | 227 (1.0)                | 992 (0.6)                   |
| 18.5-24.9                                  | 377,596 (24.6)    | 4,267 (19.5)             | 27,118 (17.6)               |
| 25-29.9                                    | 520,008 (33.9)    | 6,996 (32.0)             | 48,410 (31.5)               |
| 30-34.9                                    | 299,254 (19.5)    | 4,890 (22.3)             | 35,711 (23.2)               |
| 35-39.9                                    | 119,714 (7.8)     | 2,359 (10.8)             | 17,798 (11.6)               |
| 40+  | 58,615 (3.8)      | 1,398 (6.4)              | 10,951 (7.1)                |
| Missing                                    | 141,281 (9.2)     | 1,756 (8.0)              | 12,758 (8.3)                |
| <b>Ethnicity</b>                           |                   |                          |                             |
| White                                      | 1,088,418 (70.9)  | 15,405 (70.4)            | 108,976 (70.9)              |
| Mixed                                      | 6,536 (0.4)       | 82 (0.4)                 | 740 (0.5)                   |
| Asian or Asian British                     | 51,832 (3.4)      | 876 (4.0)                | 6,131 (4.0)                 |
| Black                                      | 17,623 (1.1)      | 179 (0.8)                | 1,915 (1.2)                 |
| Other                                      | 10,867 (0.7)      | 142 (0.6)                | 1,094 (0.7)                 |
| Missing                                    | 360,145 (23.5)    | 5,209 (23.8)             | 34,882 (22.7)               |
| <b>Index of Multiple Deprivation</b>       |                   |                          |                             |
| 1 (least deprived)                         | 312,861 (20.4)    | 3,816 (17.4)             | 26,871 (17.5)               |
| 2  | 308,559 (20.1)    | 4,003 (18.3)             | 28,848 (18.8)               |
| 3  | 307,577 (20.0)    | 4,469 (20.4)             | 30,028 (19.5)               |
| 4  | 309,012 (20.1)    | 4,729 (21.6)             | 32,698 (21.3)               |
| 5 (most deprived)                          | 297,412 (19.4)    | 4,876 (22.3)             | 35,293 (23.0)               |
| <b>Smoking status</b>                      |                   |                          |                             |
| Never                                      | 672,558 (43.8)    | 8,701 (39.7)             | 61,548 (40.0)               |
| Former                                     | 694,377 (45.2)    | 10,370 (47.4)            | 70,780 (46.0)               |
| Current                                    | 164,760 (10.7)    | 2,787 (12.7)             | 21,144 (13.8)               |
| Missing                                    | 3,726 (0.2)       | 35 (0.2)                 | 266 (0.2)                   |
| <b>Comorbidities</b>                       |                   |                          |                             |
| Hypertension                               | 626,863 (40.8)    | 9,208 (42.1)             | 57,029 (37.1)               |
| Heart Failure                              | 36,915 (2.4)      | 245 (1.1)                | 1,167 (0.8)                 |
| Other Heart Disease                        | 58,170 (3.8)      | 600 (2.7)                | 3,613 (2.4)                 |
| Diabetes                                   |                   |                          |                             |
| Controlled<br>(HbA1c <<br>58mmols/mol)     | 177,181 (11.5)    | 2,695 (12.3)             | 16,774 (10.9)               |
| Uncontrolled                               | 58,553 (3.8)      | 924 (4.2)                | 5,375 (3.5)                 |


|                            |                  |               |                |
|----------------------------|------------------|---------------|----------------|
| (HbA1c ≥ 58mmols/mol)      |                  |               |                |
| HbA1c not measured         | 3,675 (0.2)      | 48 (0.2)      | 369 (0.2)      |
| COPD                       | 86,193 (5.6)     | 1,298 (5.9)   | 7,101 (4.6)    |
| Other respiratory diseases | 38,360 (2.5)     | 555 (2.5)     | 2,875 (1.9)    |
| Cancer                     | 174,839 (11.4)   | 2,746 (12.5)  | 13,238 (8.6)   |
| Immunosuppression          | 8,496 (0.6)      | 132 (0.6)     | 862 (0.6)      |
| Chronic kidney disease     | 165,270 (10.8)   | 1,764 (8.1)   | 9,408 (6.1)    |
| Osteoarthritis             | 1,476,214 (96.1) | 20,641 (94.3) | 142,264 (92.5) |
| Rheumatoid arthritis       | 94,851 (6.2)     | 2,179 (10.0)  | 19,255 (12.5)  |
| <b>GP consultations</b>    |                  |               |                |
| Median, IQR                | 6 (3-11)         | 8 (5-14)      | 9 (5-14)       |
| Min, Max                   | 0, 585           | 0, 260        | 0, 360         |
| <b>A&amp;E attendance</b>  |                  |               |                |
| Median, IQR                | 0 (0-0)          | 0 (0-0)       | 0 (0-0)        |
| Min, Max                   | 0, 77            | 0, 59         | 0, 39          |
| <b>Vaccination</b>         |                  |               |                |
| Flu                        | 807,032 (52.6)   | 13,123 (59.9) | 73,436 (47.8)  |
| Pneumococcal               | 193,115 (12.6)   | 3,337 (15.2)  | 21,364 (13.9)  |
| <b>Medications</b>         |                  |               |                |
| Statin                     | 416,818 (27.1)   | 6,877 (31.4)  | 40,284 (26.2)  |
| Proton pump inhibitors     | 372,180 (24.2)   | 16,388 (74.9) | 121,035 (78.7) |
| Oral prednisolone          | 61,305 (4.0)     | 1,101 (5.0)   | 7,136 (4.6)    |
| Hydroxychloroquine         | 16,815 (1.1)     | 477 (2.2)     | 4,627 (3.0)    |
| Other DMARDs               | 48,752 (3.2)     | 1,220 (5.6)   | 11,479 (7.5)   |

Abbreviations: COPD, Chronic obstructive pulmonary disease; DMARDs, Disease-modifying antirheumatic drugs.

**eFigure 9. Time to COVID-19 related death by types of NSAIDs in Kaplan-Meier plot – General population**



**eFigure 10. Time to COVID-19 related death by types of NSAIDs in Kaplan-Meier plot – osteoarthritis/ rheumatoid arthritis population**



**eTable 11. Association between low dose naproxen, high dose naproxen and other NSAIDs and COVID-19 compared with non-use of NSAIDs**

|  | Number of deaths | Total person-week | Rate per 1000 | Univariable |             | Age/Sex Adjusted |             | Fully Adjusted <sup>a</sup> |             |
|--|------------------|-------------------|---------------|-------------|-------------|------------------|-------------|-----------------------------|-------------|
|  |                  |                   |               | HR          | 95% CI      | HR               | 95% CI      | HR                          | 95% CI      |
| <b>Study population 1: General population (NSAIDs prescribed cohort)</b> |                  |                   |               |             |             |                  |             |                             |             |
| <b>Non-use of NSAID</b>  | 611              | 28,052,265        | 0.02          | 1.00 (ref)  |             | 1.00 (ref)       |             | 1.00 (ref)                  |             |
| <b>Low dose naproxen</b>   | 47               | 1,639,112         | 0.03          | 1.32        | 0.98 - 1.77 | 1.02             | 0.76 - 1.37 | 0.87                        | 0.64 - 1.19 |
| <b>High dose naproxen</b>  | 88               | 4,375,351         | 0.02          | 0.92        | 0.74 - 1.16 | 1.07             | 0.85 - 1.34 | 0.93                        | 0.73 - 1.19 |
| <b>Other NSAIDs</b>  | 83               | 2,008,154         | 0.04          | 1.90        | 1.51 - 2.39 | 1.14             | 0.91 - 1.44 | 1.01                        | 0.80 - 1.29 |
| <b>Study population 2: Rheumatoid arthritis/ osteoarthritis cohort</b>   |                  |                   |               |             |             |                  |             |                             |             |
| <b>Non-use of NSAID</b>  | 2,441            | 22,630,443        | 0.11          | 1.00 (ref)  |             | 1.00 (ref)       |             | 1.00 (ref)                  |             |
| <b>Low dose naproxen</b>   | 27               | 540,784           | 0.05          | 0.46        | 0.32 - 0.68 | 0.78             | 0.53 - 1.14 | 0.72                        | 0.49 - 1.05 |
| <b>High dose naproxen</b>  | 45               | 1,234,819         | 0.04          | 0.34        | 0.25 - 0.45 | 0.87             | 0.65 - 1.18 | 0.81                        | 0.60 - 1.09 |
| <b>Other NSAIDs</b>  | 51               | 853,981           | 0.06          | 0.55        | 0.42 - 0.73 | 0.83             | 0.63 - 1.10 | 0.79                        | 0.60 - 1.05 |

<sup>a</sup>Adjusted for age, sex, obesity, smoking status, deprivation, chronic kidney disease, hypertension, heart failure, other heart diseases, diabetes severity, chronic obstructive pulmonary disease, other respiratory diseases, immunosuppression, cancer, rheumatoid arthritis (study population 1), osteoarthritis (study population 1), rheumatoid arthritis/osteoarthritis/both (study population 2), statins, proton pump inhibitors, oral prednisolone, hydroxychloroquine, other DMARDs, flu vaccine and pneumococcal vaccine.

**eTable 12. Association between COX-2 specific NSAIDs, non-specific NSAIDs with COVID-19 death compared with non-use of NSAIDs**

|  | Number of deaths | Total person-week | Rate per 1000 | Univariable |             | Age/Sex Adjusted |             | Fully Adjusted <sup>a</sup> |             |
|--|------------------|-------------------|---------------|-------------|-------------|------------------|-------------|-----------------------------|-------------|
|  |                  |                   |               | HR          | 95% CI      | HR               | 95% CI      | HR                          | 95% CI      |
| <b>Study population 1: General population (NSAIDs prescribed cohort)</b> |                  |                   |               |             |             |                  |             |                             |             |
| <b>Non-use of NSAID</b>  | 611              | 28,052,265        | 0.02          | 1.00 (ref)  |             | 1.00 (ref)       |             | 1.00 (ref)                  |             |
| <b>COX-2 specific NSAIDs</b>   | 9                | 370,569           | 0.02          | 1.12        | 0.58 - 2.15 | 0.76             | 0.40 - 1.48 | 0.61                        | 0.31 - 1.18 |
| <b>Non-specific NSAIDs</b>   | 209              | 7,652,049         | 0.03          | 1.25        | 1.07 - 1.47 | 1.10             | 0.94 - 1.29 | 0.97                        | 0.82 - 1.16 |
| <b>Study population 2: Rheumatoid arthritis/ osteoarthritis cohort</b>   |                  |                   |               |             |             |                  |             |                             |             |
| <b>Non-use of NSAID</b>  | 2,441            | 22,630,443        | 0.11          | 1.00 (ref)  |             | 1.00 (ref)       |             | 1.00 (ref)                  |             |
| <b>COX-2 specific NSAIDs</b>   | 6                | 187,763           | 0.03          | 0.30        | 0.13 - 0.66 | 0.57             | 0.25 - 1.26 | 0.49                        | 0.22 - 1.09 |
| <b>Non-specific NSAIDs</b>   | 117              | 2,441,821         | 0.05          | 0.44        | 0.37 - 0.53 | 0.86             | 0.71 - 1.03 | 0.80                        | 0.66 - 0.98 |

<sup>a</sup>Adjusted for age, sex, obesity, smoking status, deprivation, chronic kidney disease, hypertension, heart failure, other heart diseases, diabetes severity, chronic obstructive pulmonary disease, other respiratory diseases, immunosuppression, cancer, rheumatoid arthritis (study population 1), osteoarthritis (study population 1), rheumatoid arthritis/osteoarthritis/both (study population 2), statins, proton pump inhibitors, oral prednisolone, hydroxychloroquine, other DMARDs, flu vaccine and pneumococcal vaccine.

**eTable 13. Association between ibuprofen, other NSAIDs with COVID-19 death compared with non-use of NSAIDs**

|  | Number of deaths | Total person-week | Rate per 1000 | Univariable |             | Age/Sex Adjusted |             | Fully Adjusted <sup>a</sup> |             |
|--|------------------|-------------------|---------------|-------------|-------------|------------------|-------------|-----------------------------|-------------|
|  |                  |                   |               | HR          | 95% CI      | HR               | 95% CI      | HR                          | 95% CI      |
| <b>Study population 1: General population (NSAIDs prescribed cohort)</b> |                  |                   |               |             |             |                  |             |                             |             |
| <b>Non-use of NSAID</b>  | 611              | 28,052,265        | 0.02          | 1.00 (ref)  |             | 1.00 (ref)       |             | 1.00 (ref)                  |             |
| <b>Ibuprofen</b>   | 46               | 756,446           | 0.06          | 2.79        | 2.07 - 3.77 | 1.34             | 0.99 - 1.81 | 1.23                        | 0.90 - 1.67 |
| <b>Other NSAIDs</b>  | 172              | 7,266,171         | 0.02          | 1.09        | 0.92 - 1.29 | 1.03             | 0.87 - 1.22 | 0.89                        | 0.74 - 1.07 |
| <b>Study population 2: Rheumatoid arthritis/ osteoarthritis cohort</b>   |                  |                   |               |             |             |                  |             |                             |             |
| <b>Non-use of NSAID</b>  | 2441             | 22,630,443        | 0.11          | 1.00 (ref)  |             | 1.00 (ref)       |             | 1.00 (ref)                  |             |
| <b>Ibuprofen</b>   | 25               | 327,238           | 0.08          | 0.71        | 0.48 - 1.05 | 0.88             | 0.60 - 1.31 | 0.87                        | 0.59 - 1.30 |
| <b>Other NSAIDs</b>  | 98               | 2,302,346         | 0.04          | 0.39        | 0.32 - 0.48 | 0.82             | 0.67 - 1.01 | 0.76                        | 0.61 - 0.93 |

<sup>a</sup>Adjusted for age, sex, obesity, smoking status, deprivation, chronic kidney disease, hypertension, heart failure, other heart diseases, diabetes severity, chronic obstructive pulmonary disease, other respiratory diseases, immunosuppression, cancer, rheumatoid arthritis (study population 1), osteoarthritis (study population 1), rheumatoid arthritis/osteoarthritis/both (study population 2), statins, proton pump inhibitors, oral prednisolone, hydroxychloroquine, other DMARDs, flu vaccine and pneumococcal vaccine.

**eTable 14. Sensitivity analysis that excluding people ever prescribed aspirin**

|  | Number<br>of deaths | Total person-<br>week | Rate<br>per<br>1000 | Univariable |             | Age/Sex Adjusted HR |             | Fully Adjusted <sup>a</sup> |             |
|--|---------------------|-----------------------|---------------------|-------------|-------------|---------------------|-------------|-----------------------------|-------------|
|  |                     |                       |                     | HR          | 95% CI      | HR                  | 95% CI      | HR                          | 95% CI      |
| <b>Study population 1: General population (NSAIDs prescribed cohort)</b> |                     |                       |                     |             |             |                     |             |                             |             |
| <b>Non-use of NSAID</b>  | 564                 | 27,398,311            | 0.02                | 1.00 (ref)  |             | 1.00 (ref)          |             | 1.00 (ref)                  |             |
| <b>Current use of NSAIDs</b>   | 207                 | 7,789,990             | 0.03                | 1.29        | 1.10 - 1.51 | 1.11                | 0.95 - 1.30 | 0.97                        | 0.81 - 1.16 |
| <b>Study population 2: Rheumatoid arthritis/ osteoarthritis cohort</b>   |                     |                       |                     |             |             |                     |             |                             |             |
| <b>Non-use of NSAID</b>  | 2,060               | 21,149,115            | 0.10                | 1.00 (ref)  |             | 1.00 (ref)          |             | 1.00 (ref)                  |             |
| <b>Current use of NSAIDs</b>   | 117                 | 2,502,406             | 0.05                | 0.48        | 0.40 - 0.58 | 0.90                | 0.75 - 1.09 | 0.84                        | 0.69 - 1.03 |

<sup>a</sup>Adjusted for age, sex, obesity, smoking status, deprivation, chronic kidney disease, hypertension, heart failure, other heart diseases, diabetes severity, chronic obstructive pulmonary disease, other respiratory diseases, immunosuppression, cancer, rheumatoid arthritis (study population 1), osteoarthritis (study population 1), rheumatoid arthritis/osteoarthritis/both (study population 2), statins, proton pump inhibitors, oral prednisolone, hydroxychloroquine, other DMARDs, flu vaccine, and pneumococcal vaccine.

**eTable 15. Post-hoc analysis that using Directed Acyclic Graph approach to select covariates**

|  | Full cohort      |                   |               |                       |             | Complete case cohort |                   |               |                       |             |                       |             |  |  |  |  |  |  |  |  |
|--|------------------|-------------------|---------------|-----------------------|-------------|----------------------|-------------------|---------------|-----------------------|-------------|-----------------------|-------------|--|--|--|--|--|--|--|--|
|  | Number of deaths | Total person-week | Rate per 1000 | Adjusted <sup>a</sup> |             | Number of deaths     | Total person-week | Rate per 1000 | Adjusted <sup>b</sup> |             | Adjusted <sup>c</sup> |             |  |  |  |  |  |  |  |  |
|  |                  |                   |               |                       |             |                      |                   |               | HR                    | 95% CI      | HR                    | 95% CI      |  |  |  |  |  |  |  |  |
| <b>Study population 1: General population (NSAIDs prescribed cohort)</b> |                  |                   |               |                       |             |                      |                   |               |                       |             |                       |             |  |  |  |  |  |  |  |  |
| Non-use of NSAID   | 611              | 28,052,265        | 0.02          | 1.00 (ref)            |             | 462                  | 21,597,607        | 0.02          | 1.00 (ref)            |             | 1.00 (ref)            |             |  |  |  |  |  |  |  |  |
| Current use of NSAIDs  | 218              | 8,022,617         | 0.03          | 1.11                  | 0.95 - 1.30 | 165                  | 6,151,801         | 0.03          | 1.12                  | 0.94 - 1.34 | 1.13                  | 0.94 - 1.35 |  |  |  |  |  |  |  |  |
| <b>Study population 2: Rheumatoid arthritis/ osteoarthritis cohort</b>   |                  |                   |               |                       |             |                      |                   |               |                       |             |                       |             |  |  |  |  |  |  |  |  |
| Non-use of NSAID   | 2441             | 22,630,443        | 0.11          | 1.00 (ref)            |             | 1,809                | 17,320,859        | 0.10          | 1.00 (ref)            |             | 1.00 (ref)            |             |  |  |  |  |  |  |  |  |
| Current use of NSAIDs  | 123              | 2,629,585         | 0.05          | 0.86                  | 0.72 - 1.03 | 86                   | 2,029,579         | 0.04          | 0.80                  | 0.64 – 0.99 | 0.80                  | 0.64 - 0.99 |  |  |  |  |  |  |  |  |

<sup>a</sup>Included all covariates selected using DAG approach except ethnicity in full cohort. Adjusted for age, sex, obesity, smoking status, deprivation, chronic kidney disease, hypertension, heart failure, other heart diseases, diabetes severity, chronic obstructive pulmonary disease, other respiratory diseases, immunosuppression, cancer, rheumatoid arthritis (study population 1), osteoarthritis (study population 1), rheumatoid arthritis/osteoarthritis/both (study population 2), oral prednisolone, hydroxychloroquine, other DMARDs, and A&E attendance.

<sup>b</sup>Included all covariates selected using DAG approach except ethnicity in complete case cohort. Adjusted for age, sex, obesity, smoking status, deprivation, chronic kidney disease, hypertension, heart failure, other heart diseases, diabetes severity, chronic obstructive pulmonary disease, other respiratory diseases, immunosuppression, cancer, rheumatoid arthritis (study population 1), osteoarthritis (study population 1), rheumatoid arthritis/osteoarthritis/both (study population 2), oral prednisolone, hydroxychloroquine, other DMARDs, ethnicity and A&E attendance.

<sup>c</sup>Included all covariates selected using DAG approach in complete case cohort. Adjusted for age, sex, obesity, smoking status, deprivation, chronic kidney disease, hypertension, heart failure, other heart diseases, diabetes severity, chronic obstructive pulmonary disease, other respiratory diseases, immunosuppression, cancer, rheumatoid arthritis (study population 1), osteoarthritis (study population 1), rheumatoid arthritis/osteoarthritis/both (study population 2), oral prednisolone, hydroxychloroquine, other DMARDs, ethnicity and A&E attendance.

**eTable 16. Sensitivity analysis that additionally adjusting for ethnicity in the fully adjusted models**

|  | Number of deaths | Total person-week | Rate per 1000 | Univariable |             | Age/Sex Adjusted |             | Fully Adjusted <sup>a</sup> |             |
|--|------------------|-------------------|---------------|-------------|-------------|------------------|-------------|-----------------------------|-------------|
|  |                  |                   |               | HR          | 95% CI      | HR               | 95% CI      | HR                          | 95% CI      |
| <b>Study population 1: General population (NSAIDs prescribed cohort)</b> |                  |                   |               |             |             |                  |             |                             |             |
| <b>Non-use of NSAID</b>  | 462              | 21,597,607        | 0.02          | 1.00 (ref)  |             | 1.00 (ref)       |             | 1.00 (ref)                  |             |
| <b>Current use of NSAIDs</b>   | 165              | 6,151,801         | 0.03          | 1.25        | 1.05 - 1.50 | 1.09             | 0.91 - 1.30 | 1.01                        | 0.83 - 1.24 |
| <b>Study population 2: Rheumatoid arthritis/ osteoarthritis cohort</b>   |                  |                   |               |             |             |                  |             |                             |             |
| <b>Non-use of NSAID</b>  | 1,809            | 17,320,859        | 0.10          | 1.00 (ref)  |             | 1.00 (ref)       |             | 1.00 (ref)                  |             |
| <b>Current use of NSAIDs</b>   | 86               | 2,029,579         | 0.04          | 0.41        | 0.33 - 0.50 | 0.78             | 0.63 - 0.97 | 0.73                        | 0.58 - 0.91 |

<sup>a</sup>Adjusted for age, sex, obesity, smoking status, deprivation, chronic kidney disease, hypertension, heart failure, other heart diseases, diabetes severity, chronic obstructive pulmonary disease, other respiratory diseases, immunosuppression, cancer, rheumatoid arthritis (study population 1), osteoarthritis (study population 1), rheumatoid arthritis/osteoarthritis/both (study population 2), statins, proton pump inhibitors, oral prednisolone, hydroxychloroquine, other DMARDs, flu vaccine, pneumococcal vaccine and ethnicity. Complete case analysis was conducted for addressing missing data.

**eTable 17. Sensitivity analysis that additionally adjusted for GP consultation and A&E attendance in the fully adjusted models**

|  | Number of deaths | Total person-week | Rate per 1000 | Univariable |             | Age/Sex Adjusted |             | Fully Adjusted <sup>a</sup> |             |
|--|------------------|-------------------|---------------|-------------|-------------|------------------|-------------|-----------------------------|-------------|
|  |                  |                   |               | HR          | 95% CI      | HR               | 95% CI      | HR                          | 95% CI      |
| <b>Study population 1: General population (NSAIDs prescribed cohort)</b> |                  |                   |               |             |             |                  |             |                             |             |
| <b>Non-use of NSAID</b>  | 611              | 28,052,265        | 0.02          | 1.00 (ref)  |             | 1.00 (ref)       |             | 1.00 (ref)                  |             |
| <b>Current use of NSAIDs</b>   | 218              | 8,022,617         | 0.03          | 1.25        | 1.07 - 1.46 | 1.08             | 0.93 - 1.27 | 0.97                        | 0.82 - 1.16 |
| <b>Study population 2: Rheumatoid arthritis/ osteoarthritis cohort</b>   |                  |                   |               |             |             |                  |             |                             |             |
| <b>Non-use of NSAID</b>  | 2441             | 22,630,443        | 0.11          | 1.00 (ref)  |             | 1.00 (ref)       |             | 1.00 (ref)                  |             |
| <b>Current use of NSAIDs</b>   | 123              | 2,629,585         | 0.05          | 0.43        | 0.36 - 0.52 | 0.84             | 0.70 - 1.00 | 0.81                        | 0.67 - 0.98 |

<sup>a</sup>Adjusted for age, sex, obesity, smoking status, deprivation, chronic kidney disease, hypertension, heart failure, other heart diseases, diabetes severity, chronic obstructive pulmonary disease, other respiratory diseases, immunosuppression, cancer, rheumatoid arthritis (study population 1), osteoarthritis (study population 1), rheumatoid arthritis/osteoarthritis/both (study population 2), statins, proton pump inhibitors, oral prednisolone, hydroxychloroquine, other DMARDs, flu vaccine, pneumococcal vaccine, and GP consultations and A&E attendances in the past year.

**eTable 18. Sensitivity analysis that separating HbA1c no measures category from uncontrolled diabetes category in the fully adjusted models**

|  | Number of deaths | Total person-week | Rate per 1000 | Fully Adjusted <sup>a</sup><br>(Main analysis) |             | Fully Adjusted <sup>b</sup><br>(separating HbA1c no measures category from uncontrolled diabetes category) |             |
|--|------------------|-------------------|---------------|--|-------------|--|-------------|
|  |                  |                   |               | HR   | 95% CI      | HR   | 95% CI      |
| <b>Study population 1: General population (NSAIDs prescribed cohort)</b> |                  |                   |               |  |             |  |             |
| <b>Non-use of NSAID</b>  | 611              | 28,052,265        | 0.02          | 1.00 (ref)                                     |             | 1.00 (ref)   |             |
| <b>Current use of NSAIDs</b>   | 218              | 8,022,617         | 0.03          | 0.95   | 0.80 - 1.13 | 0.95   | 0.80 - 1.13 |
| <b>Study population 2: Rheumatoid arthritis/ osteoarthritis cohort</b>   |                  |                   |               |  |             |  |             |
| <b>Non-use of NSAID</b>  | 2,441            | 22,630,443        | 0.11          | 1.00 (ref)                                     |             | 1.00 (ref)   |             |
| <b>Current use of NSAIDs</b>   | 123              | 2,629,585         | 0.05          | 0.78   | 0.65 - 0.94 | 0.78   | 0.65 - 0.94 |

<sup>a</sup>Adjusted for age, sex, obesity, smoking status, deprivation, chronic kidney disease, hypertension, heart failure, other heart diseases, diabetes severity (three categories: no diabetes, controlled diabetes, uncontrolled diabetes), chronic obstructive pulmonary disease, other respiratory diseases, immunosuppression, cancer, rheumatoid arthritis (study population 1), osteoarthritis (study population 1), rheumatoid arthritis/osteoarthritis/both (study population 2), statins, proton pump inhibitors, oral prednisolone, hydroxychloroquine, other DMARDs, flu vaccine and pneumococcal vaccine.

<sup>b</sup>Adjusted for age, sex, obesity, smoking status, deprivation, chronic kidney disease, hypertension, heart failure, other heart diseases, diabetes severity (four categories: no diabetes, controlled diabetes, uncontrolled diabetes, diabetes without HbA1c measures), chronic obstructive pulmonary disease, other respiratory diseases, immunosuppression, cancer, rheumatoid arthritis (study population 1), osteoarthritis (study population 1), rheumatoid arthritis/osteoarthritis/both (study population 2), statins, proton pump inhibitors, oral prednisolone, hydroxychloroquine, other DMARDs, flu vaccine and pneumococcal vaccine.

**eTable 19. Sensitivity analysis that using 2 months to be the timeframe to identify exposure status**

|  | Number of deaths | Total person-week | Rate per 1000 | Univariable |             | Age/Sex Adjusted |             | Fully Adjusted <sup>a</sup> |             |
|--|------------------|-------------------|---------------|-------------|-------------|------------------|-------------|-----------------------------|-------------|
|  |                  |                   |               | HR          | 95% CI      | HR               | 95% CI      | HR                          | 95% CI      |
| <b>Study population 1: General population (NSAIDs prescribed cohort)</b> |                  |                   |               |             |             |                  |             |                             |             |
| <b>Non-use of NSAID</b>  | 664              | 30,643,195        | 0.02          | 1.00 (ref)  |             | 1.00 (ref)       |             | 1.00 (ref)                  |             |
| <b>Current use of NSAIDs</b>   | 165              | 5,431,686         | 0.03          | 1.40        | 1.18 - 1.66 | 1.15             | 0.97 - 1.37 | 1.03                        | 0.85 - 1.24 |
| <b>Study population 2: Rheumatoid arthritis/ osteoarthritis cohort</b>   |                  |                   |               |             |             |                  |             |                             |             |
| <b>Non-use of NSAID</b>  | 2,475            | 23,296,574        | 0.11          | 1.00 (ref)  |             | 1.00 (ref)       |             | 1.00 (ref)                  |             |
| <b>Current use of NSAIDs</b>   | 89               | 1,963,452         | 0.05          | 0.43        | 0.35 - 0.53 | 0.82             | 0.66 - 1.01 | 0.76                        | 0.61 - 0.94 |

<sup>a</sup>Adjusted for age, sex, obesity, smoking status, deprivation, chronic kidney disease, hypertension, heart failure, other heart diseases, diabetes severity, chronic obstructive pulmonary disease, other respiratory diseases, immunosuppression, cancer, rheumatoid arthritis (study population 1), osteoarthritis (study population 1), rheumatoid arthritis/osteoarthritis/both (study population 2), statins, proton pump inhibitors, oral prednisolone, hydroxychloroquine, other DMARDs, flu vaccine, and pneumococcal vaccine.

**eTable 20. Sensitivity analysis that removing indomethacin from exposure of interest**

|  | Number of deaths | Total person-week | Rate per 1000 | Univariable |             | Age/Sex Adjusted |             | Fully Adjusted <sup>a</sup> |             |
|--|------------------|-------------------|---------------|-------------|-------------|------------------|-------------|-----------------------------|-------------|
|  |                  |                   |               | HR          | 95% CI      | HR               | 95% CI      | HR                          | 95% CI      |
| <b>Study population 1: General population (NSAIDs prescribed cohort)</b> |                  |                   |               |             |             |                  |             |                             |             |
| Non-use of NSAID   | 611              | 28,052,265        | 0.02          | 1.00 (ref)  |             | 1.00 (ref)       |             | 1.00 (ref)                  |             |
| Current use of NSAIDs  | 215              | 7,945,777         | 0.03          | 1.24        | 1.06 - 1.45 | 1.08             | 0.93 - 1.27 | 0.95                        | 0.80 - 1.13 |
| <b>Study population 2: Rheumatoid arthritis/ osteoarthritis cohort</b>   |                  |                   |               |             |             |                  |             |                             |             |
| Non-use of NSAID   | 2,441            | 22,630,443        | 0.11          | 1.00 (ref)  |             | 1.00 (ref)       |             | 1.00 (ref)                  |             |
| Current use of NSAIDs  | 122              | 2,606,365         | 0.05          | 0.43        | 0.36 - 0.52 | 0.84             | 0.70 - 1.01 | 0.78                        | 0.65 - 0.95 |

<sup>a</sup>Adjusted for age, sex, obesity, smoking status, deprivation, chronic kidney disease, hypertension, heart failure, other heart diseases, diabetes severity, chronic obstructive pulmonary disease, other respiratory diseases, immunosuppression, cancer, rheumatoid arthritis (study population 1), osteoarthritis (study population 1), rheumatoid arthritis/osteoarthritis/both (study population 2), statins, proton pump inhibitors, oral prednisolone, hydroxychloroquine, other DMARDs, flu vaccine, and pneumococcal vaccine.

**eTable 21. Sensitivity analysis that not censoring people at NSAID prescription after study start date in the non-use of NSAID group as an intention-to-treat analysis**

|  | Number of deaths | Total person-week | Rate per 1000 | Univariable |             | Age/Sex Adjusted |             | Fully Adjusted <sup>a</sup> |             |
|--|------------------|-------------------|---------------|-------------|-------------|------------------|-------------|-----------------------------|-------------|
|  |                  |                   |               | HR          | 95% CI      | HR               | 95% CI      | HR                          | 95% CI      |
| <b>Study population 1: General population (NSAIDs prescribed cohort)</b> |                  |                   |               |             |             |                  |             |                             |             |
| <b>Non-use of NSAID</b>  | 624              | 28,838,005        | 0.02          | 1.00 (ref)  |             | 1.00 (ref)       |             | 1.00 (ref)                  |             |
| <b>Current use of NSAIDs</b>   | 218              | 8,022,617         | 0.03          | 1.26        | 1.08 - 1.47 | 1.09             | 0.93 - 1.27 | 0.96                        | 0.80 - 1.13 |
| <b>Study population 2: Rheumatoid arthritis/ osteoarthritis cohort</b>   |                  |                   |               |             |             |                  |             |                             |             |
| <b>Non-use of NSAID</b>  | 2,455            | 22,949,504        | 0.11          | 1.00 (ref)  |             | 1.00 (ref)       |             | 1.00 (ref)                  |             |
| <b>Current use of NSAIDs</b>   | 123              | 2,629,585         | 0.05          | 0.44        | 0.36 - 0.52 | 0.84             | 0.70 - 1.00 | 0.78                        | 0.65 - 0.94 |

<sup>a</sup>Adjusted for age, sex, obesity, smoking status, deprivation, chronic kidney disease, hypertension, heart failure, other heart diseases, diabetes severity, chronic obstructive pulmonary disease, other respiratory diseases, immunosuppression, cancer, rheumatoid arthritis (study population 1), osteoarthritis (study population 1), rheumatoid arthritis/osteoarthritis/both (study population 2), statins, proton pump inhibitors, oral prednisolone, hydroxychloroquine, other DMARDs, flu vaccine, and pneumococcal vaccine

eFigure 11. E-value for the upper 95% CI and point estimate in people with rheumatoid arthritis/ osteoarthritis

